|
Sign In to gain access to subscriptions and/or personal tools.
|
The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia Cytokines in SLE
Daniel J. Wallace
Cedars-Sinai Medical Center, Los Angeles, CA
Mariana Linker-Israeli
Cedars-Sinai Medical Center, Los Angeles, CA
Allan L. Metzger
UCLA School of Medicine, Los Angeles, CA
Vera J. Stecher
Sanofi-Winthrop Pharmaceuticals, New York, NY, USA
Hydroxychloroquine has several less well-known actions that may have clinical relevance in treating systemic lupus erythematosus (SLE). (1) Hydroxychloroquine has a possible antithrombotic action. It is a platelet inhibitor and appears to decrease the risk of thromboembolism in patients with anticardiolipin antibodies. (2) Hydroxychloroquine is associated with lower serum cholesterol and low-density lipoprotein levels compared to those present in patients who are taking corticosteroids but not antimalarials for SLE. (3) It may also decrease abnormal levels of cytokines. Interleukin-6 (IL-6), soluble CD8 and soluble IL-2 receptors (sIL-2R) are lower in patients taking antimalarials compared to those on corticosteroids alone or on neither medication. Serum levels of CD8 and sIL-2R decrease after 6 weeks of hydroxychloroquine treatment. These findings may help explain the favorable response of SLE patients treated with antimalarials.
Key Words: Hydroxychloroquine • Chloroquine • Lupus • Hyperlipidemia • Cytokines
Lupus, Vol. 2, No. 1 suppl,
S13-S15 (1993)
DOI: 10.1177/096120339300200104
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R Kaiser, C M Cleveland, and L A Criswell
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort
Ann Rheum Dis,
February 1, 2009;
68(2):
238 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Ruiz-Irastorza, M-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain, and C Aguirre
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Lupus,
September 1, 2006;
15(9):
577 - 583.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. T. Ho, C. W. Ahn, G. S. Alarcon, B. A. Baethge, F. K. Tan, J. Roseman, H. M. Bastian, B. J. Fessler, G. McGwin Jr, L. M. Vila, et al.
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events
Rheumatology,
October 1, 2005;
44(10):
1303 - 1307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Toubi, A Kessel, I Rosner, M Rozenbaum, M Lorber, D Paran, E Sabo, and T D Golan
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE
Lupus,
April 1, 2003;
12(4):
297 - 301.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S E Lane, K Gaffney, R Y Ball, and T J Marshall
Grand Rounds from International Lupus Centres: A swollen leg unmasks longstanding SLE
Lupus,
January 1, 2001;
10(1):
4 - 8.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Walchner, G. Messer, and P. Kind
Phototesting and photoprotection in LE
Lupus,
January 1, 1997;
6(2):
167 - 174.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. Meinao, E. Sato, L. Andrade, M. Ferraz, and E. Atra
Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
Lupus,
June 1, 1996;
5(3):
237 - 241.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Wallace
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review
Lupus,
June 1, 1996;
5(1_suppl):
S59 - S64.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Khamashta, N. Buchanan, and G. Hughes
The use of hydroxychloroquine in lupus pregnancy : the British experience
Lupus,
June 1, 1996;
5(1_suppl):
S65 - S66.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J.-C. Piette
Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome
Lupus,
April 1, 1994;
3(2):
73 - 74.
[PDF]
|
|
|
|
|
